Business Wire

MASIMO

23.5.2022 08:02:06 CEST | Business Wire | Press release

Share
New Study Finds That Masimo PVi® May Be Useful in Helping ER Doctors Determine the Severity of Asthma Attacks in Pediatric Patients

Masimo (NASDAQ: MASI) today announced the findings of a retrospective study published in the American Journal of Emergency Medicine in which Dr. Gülsah Demir and colleagues at Tepecik Research and Training Hospital in Izmir, Turkey investigated the potential ability of Masimo PVi® to guide emergency room triage decisions for pediatric patients with signs of obstructive respiratory disease, such as an asthma attack. PVi, or pleth variability index, is a noninvasive measurement of changes in perfusion index that occur during one or more respiratory cycles. The researchers concluded that “Automatic PVi measurement can be used as a noninvasive, rapid, and objective tool in the emergency department triage of patients admitted to the pediatric emergency department with signs of asthma attack or reactive respiratory tract disease.”1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220522005068/en/

Acute asthma attack is a common cause of admission to emergency departments (EDs) among children, and triage by severity is important for determining appropriate clinical treatment.2,3 Noting that PVi has been shown to be an accurate method for measuring the degree of pulsus paradoxus,4,5 a reduction in systolic blood pressure associated with obstructive respiratory tract disease, the authors sought to understand whether PVi might be of assistance to ED clinicians needing to make rapid triage decisions in such cases. They enrolled 133 patients between the ages of 2 and 18 (median age 5 years old) who arrived at the ED between May 2020 and July 2021 with a diagnosis of asthma attack or reactive respiratory tract disease. During initial examination and after treatment, patients’ PVi levels were measured using Masimo Radical-7® Pulse CO-Oximeters® . Severity of the asthma attack/respiratory disease was graded using the Pulmonary Index Score (PIS). Treatment decisions, including to hospitalize or to discharge, were made by clinicians who were blinded to PVi values.

The researchers found that PVi values, both before and after treatment, were significantly higher in patients with “severe” disease, compared to “mild” or “moderate” disease (p < 0.001): “Severe” patients had median PVi values of 47% (42 – 51) before treatment and 38% (32 – 44) after treatment; “moderate” patients, 31.5% (26 – 39) before and 25% (20 – 29) after; and “mild” patients, 24% (19 – 27) before and 19.5% (17 – 22) after. PVi values were also significantly higher for patients who were hospitalized, compared to those who were discharged from the ED (p < 0.001): Hospitalized patients had median PVi values of 46.5% (39 – 49) before treatment and 38% (29 – 44) after treatment; discharged patients, 26% (22 – 34) before and 21% (18 – 26) after. For all severity levels, post-treatment PVi values were significantly lower than pre-treatment values (p < 0.001). The researchers calculated a pre-treatment PVi cut-off level of 37.5% for predicting whether a patient had “severe” disease (68.75% positive predictive power, with 100% sensitivity and 85% specificity, p < 0.001) and would require hospitalization (72.34% positive predictive power, with 91.89% sensitivity and 71.74% specificity, p < 0.001).

The authors concluded, “The severity of attacks of many patients who apply to the pediatric emergency department because of an attack due to obstructive respiratory tract diseases can be accurately defined with certain clinical evaluation tools. Although PIS is a very important tool for assessing attack severity, it includes some subjective parameters. Automatic PVi measurement can be useful in intensive emergency department conditions, especially in triage, in terms of predicting the response of patients to treatment and follow-up results by quickly determining the severity of attacks, and in terms of reducing subjective clinical decision variations among physicians. This is because it provides objective data.”

In the U.S., PVi is cleared as a noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients.

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.6 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,7 improve CCHD screening in newborns,8 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.9-12 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,13 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2021-22 U.S. News and World Report Best Hospitals Honor Roll.14 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb® ), oxygen content (SpOC™), carboxyhemoglobin (SpCO® ), methemoglobin (SpMet® ), Pleth Variability Index (PVi® ), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67® , fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97® . Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica® , Halo ION™, UniView® , UniView :60™, and Masimo SafetyNet® . In 2022, Masimo acquired Sound United, a leading developer of premium consumer sound and home integration technologies, whose brand include Bowers & Wilkins® , Denon® , Polk Audio® , Marantz® , Definitive Technology® , Classé® , and Boston Acoustics® . Additional information about Masimo and its products may be found at www.masimo.com . Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/ .

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Demir G, Berksoy E, Bardak S, Elibol P, Çiçek A, Özon A, Nalbant T, Gölkap G. Use of the pleth variability index in children with obstructive respiratory disease. Amer J Emerg Med. 11 Mar 2022. DOI: https://doi.org/10.1016/j.ajem.2022.03.019 .
  2. Network, B.T.S.S.I.G. British guideline on the management of asthma [Internet]. 2016 [cited 2019 June 26]. Available from: https://www.brit-thoracic.org.uk/qualityimprovement/guidelines/asthma/
  3. Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46(3):622‐39.doi: 10.1183/13993003.00853-2015.
  4. G Krishnan S, Wong HC, Ganapathy S, Ong GY. Oximetry-detected pulsus paradoxus predicts for severity in paediatric asthma. Arch Dis Child. 2020 Jun;105(6):533-38. doi: 10.1136/archdischild-2019-318043.
  5. Brandwein A, Patel K, Kline M, Silver P, Gangadharan S. Using pleth variability as a triage tool for children with obstructive airway disease in a pediatric emergency department. Pediatr Emerg Care. 2018;34(10):702-5. doi: 10.1097/PEC.0000000000000887.
  6. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com . Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  7. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  8. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  9. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology . 2010:112(2):282-287.
  10. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter . Spring-Summer 2012.
  11. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety . 2016 Jul;42(7):293-302.
  12. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
  13. Estimate: Masimo data on file.
  14. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview .

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo PVi® . These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique technologies, including PVi, contribute to positive clinical outcomes and patient safety; risks that the researchers’ conclusions and findings may be inaccurate; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release

Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo

North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release

Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene

Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release

Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req

From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release

The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye